Immunome (IMNM) Corporate presentation summary

Strategic vision and leadership

• Aims to establish a premier targeted oncology company with a robust pipeline and proven leadership team.

• Leadership includes executives with track records in developing FDA-approved drugs and building high-value biotech companies.

Lead asset: Varegacestat for desmoid tumors

• Oral, once-daily gamma secretase inhibitor demonstrated positive Phase 3 topline data, meeting all primary and key secondary endpoints.

• Achieved 84% reduction in risk of progression or death vs placebo and a 56% objective response rate.

• Generally well-tolerated with manageable safety profile; most adverse events were mild to moderate.

• NDA submission planned for 2Q 2026, targeting standard of care status.

Market opportunity and launch strategy

• Desmoid tumors are rare, locally aggressive, and often affect young adults, with limited approved therapies.

• Launch strategy focuses on patient initiation, adherence, and expanding reach through treatment centers.

• Market includes 10,000–11,000 actively managed patients in the US.